Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Hemostemix Inc V.HEM

Alternate Symbol(s):  HMTXF

Hemostemix Inc. is a Canada-based clinical-stage biotechnology company. The Company’s principal business is to develop, manufacture and commercialize blood-derived stem cell therapies to treat various diseases. It is an autologous stem cell therapeutics company that holds 91 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01 is a lead clinical-stage candidate, like NCP-01 and CCP-01, is generated from the patient’s blood. The Company is engaged in providing treatment for ischemia, such as ischemic cardiomyopathy, angina, peripheral arterial disease including critical limb ischemia. The Company’s proprietary technology is a personalized regenerative therapy that is administered to a patient within seven days of the initial blood draw. Its subsidiaries include Kwalata Trading Limited, Hemostemix Ltd., and PreCerv Inc.


TSXV:HEM - Post by User

Comment by WalterTheDawgon May 17, 2022 3:28pm
118 Views
Post# 34690086

RE:RE:RE:RE:RE:RE:RE:Great News!

RE:RE:RE:RE:RE:RE:RE:Great News!For sure. I don't know what that means but he's said it a bunch of times and I'm not sure if he's just playing it safe with regards to what results might be or if they already know they aren't great and are trying to prepare investors or what but at the same time they are saying they hope to begin a phase 3 this year and there is no way they would get the go ahead for that without solid efficacy proven through a double blind randomly controlled trial such as our phase 2. Honestly I have no idea what to expect moving forward but I'm hopefull that management will provide some positive guidance moving forward and not just more dilution. We've all been waiting a long time and spent a lot on this company in the hopes of seeing ACP 01 proven as an effective treatment for CLI. Safety is important but I'm fairly certain no one is questioning whether or not it's safe as 500 people treated with no safety issues is a pretty good track record. Hiring this Rick guy now tells me we will see more financing prior to results which would not be a good sign in my opinion. Although im sure we are drowning in legal fees and tapped out from the settlement and now we need to pay for the analysis. No idea what that costs or how long it may take. Good luck fellas
<< Previous
Bullboard Posts
Next >>